Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19073223 | 0.72 | KDM4E (0.36) | KCNA3KDM4EMAPK1LMNACYP1A1 | |
| SCHEMBL12766723 | 0.71 | MCL1 (0.38) | ERN1HDAC3NUAK1IGF1RMET | |
| SCHEMBL11000514 | 0.69 | MAPT (0.40) | KCNA3MAPK1LMNAPADI4ALDH1A1 | |
| SCHEMBL9798800 | 0.69 | MAPT (0.39) | KCNA3KDM4EMAPK1LMNACYP1A1 | |
| SCHEMBL9798793 | 0.69 | MAPT (0.39) | KCNA3KDM4EMAPK1LMNACYP1A1 | |
| SCHEMBL15447924 | 0.68 | KDM4E (0.33) | KCNA3KDM4EMAPK1LMNACYP1A1 | |
| SCHEMBL10921321 | 0.67 | KCNA3 (0.43) | KCNA3MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL12766724 | 0.67 | CYP3A4 (0.37) | ERN1HDAC3NUAK1IGF1RMET | |
| SCHEMBL21929661 | 0.66 | MAOB (0.44) | ERN1HDAC3NUAK1IGF1RMET | |
| SCHEMBL11953498 | 0.66 | MAOB (0.44) | ERN1HDAC3NUAK1IGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| US-9241942-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885HDAC3 1564/4885NUAK1 2518/4885 |
| US-20160168116-A1 | IRE-1alpha Inhibitors | XBP1, DDIT3, ERN1 | ERN1 3/4885HDAC3 1564/4885NUAK1 2518/4885 |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885HDAC3 1564/4885NUAK1 2518/4885 |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885HDAC3 1564/4885NUAK1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.